Ciprofloxacin, nimodipine duties
Executive Summary
Trade duties would continue to be suspended through Jan. 1, 1995 under Rep. DeLauro's (D-Conn.) HR 4248 introduced Feb. 19. Ciprofloxacin HCI is the active ingredient in the broad spectrum antibiotic Cipro and nimodipine the active ingredient in the calcium channel blocker Nimotop, both manufactured in DeLauro's West Haven home district by Miles Pharmaceutical Division. DeLauro's HR 4247 would also suspend duties on nimodipine tablets.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth